Skyrizi^® ,

Risankizumab-rzaa

Disease

Crohn's disease , Ulcerative colitis ,

Drug Class

Biologics/Biosimilars

Delivery Method

IV or Injection

Brand name:

Skyrizi^® ,

Drug name:

Risankizumab-rzaa

Drug type

Interleukin-23 Antagonist

Recommendations for pregnancy

Insufficient trial data. Monoclonal antibodies may be transported across the placenta

Most common side effects

It may increase risk of infections including upper respiratory or urinary tract infections. Other side effects may include injection site reactions, abdominal pain, headache, and joint pains. Liver injury has been reported (liver enzymes and bilirubin levels should be monitored).

Other

Patients should be evaluated for tuberculosis (TB) prior to starting this medication, and should not be given Skyrizi® if there is active TB. If there is a hypersensitivity reaction or anaphylaxis occurs, discontinue medication and initiate appropriate therapy immediately. Avoid use of live vaccines

Learn more about Biologics/Biosimilars

Link

View other biologics